Loading
Louis Staudt defined the molecular subtypes of large B-cell lymphoma that guide targeted therapy.
Louis M. Staudt is Director of the Center for Cancer Genomics and Chief of the Lymphoid Malignancies Branch at the National Cancer Institute. He is known for defining the molecular subtypes of diffuse large B-cell lymphoma that guide targeted therapy, discovering the germinal-centre and activated B-cell subtypes and the chronic active B-cell receptor signalling that made BTK inhibitors work in lymphoma. His selected papers report distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, and review the genetics and pathogenesis of the disease. He now directs NCI's cancer genomics centre.
| Title | Journal | Year |
|---|---|---|
| Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Nature | 2000 |
| Genetics and pathogenesis of diffuse large B-cell lymphoma | New England Journal of Medicine | 2018 |
The piece that turns a research classification into something a trial can use on one person's biopsy, with a probability attached rather than a flat label. It is the reason genetics-directed lymphoma trials became possible at all.
The genetic nosology that precision-medicine trials in diffuse large B-cell lymphoma now use to pick patients. It gives a mechanism, not just a label: two of the four subtypes point at a drug class that already exists.
The reason a pathology report on diffuse large B-cell lymphoma says germinal-centre or non-germinal-centre, and the origin of every attempt since to treat the two differently. It also made the case that microarray profiling could do something the clinical index could not, which is what pulled genomics into haematology.
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH), Diffuse large B-cell lymphoma.
Shares A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications, Genetics and pathogenesis of diffuse large B-cell lymphoma, BTK (Bruton tyrosine kinase), Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.
Shares The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma.
Shares The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma, A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma.
Shares The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma, A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications, Genetics and pathogenesis of diffuse large B-cell lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).